GENMAB AS SPON ADS EACH REP 0.1 ORD SHS
Genmab A/S (GMAB) is a Denmark-based biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. Investors should know it operates a dual model: advancing an internal pipeline while partnering with large pharmaceutical companies to co-develop and commercialise candidates, generating revenue through milestones, royalties and licence fees. The company’s strengths include proprietary antibody platforms and experience progressing programmes through late‑stage development, which can enhance the value of partnered assets. That said, biotech investing carries higher risk — clinical setbacks, regulatory decisions, patent disputes and market competition can materially affect outlook and share price. Genmab’s market capitalisation (about $19.13bn) reflects significant investor confidence, but future returns are uncertain. Investors may watch clinical readouts, partnership updates and cash runway. This is general educational information and not personalised financial advice; consider your own suitability and consult a professional if needed.
Why It's Moving
Genmab Shareholders Endorse Robust 2025 Profit at AGM, Signaling Strong Financial Health Ahead of 2026 Growth
- Shareholders approved carrying forward USD 963 million in 2025 profits, underscoring Genmab's ability to generate hefty earnings from its antibody portfolio.
- Board authorized a DKK 1,900,000 share capital reduction via treasury share cancellation, potentially boosting earnings per share for remaining holders.
- Six directors re-elected and Deloitte re-appointed as auditor, providing continuity in governance amid anticipation for next growth phase.
Genmab Shareholders Endorse Robust 2025 Profit at AGM, Signaling Strong Financial Health Ahead of 2026 Growth
- Shareholders approved carrying forward USD 963 million in 2025 profits, underscoring Genmab's ability to generate hefty earnings from its antibody portfolio.
- Board authorized a DKK 1,900,000 share capital reduction via treasury share cancellation, potentially boosting earnings per share for remaining holders.
- Six directors re-elected and Deloitte re-appointed as auditor, providing continuity in governance amid anticipation for next growth phase.
When is the next earnings date for GENMAB AS SPON ADS EACH REP 0.1 ORD SHS (GMAB)?
Genmab A/S (GMAB) is scheduled to report its next earnings on May 7, 2026, covering the first quarter of 2026. The company typically releases earnings in early May based on its historical reporting pattern. This upcoming report will provide investors with insight into the company's Q1 2026 financial performance, including revenue and earnings per share metrics.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Genmab's stock with a target price of $39.2, indicating strong growth potential.
Financial Health
Genmab is achieving strong sales and profits, with significant cash generation and high profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ARCELLX INC
Develops T-cell therapies for the treatment of cancer.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring GMAB
Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory decisions can be major value drivers, though trial outcomes are uncertain and timelines can shift.
Partner-led Revenue
Collaborations with large pharmaceutical firms provide milestone and royalty income, offering diversification but depending on partner execution.
Proprietary Platforms
Genmab’s antibody technologies can speed discovery and create long-term opportunity, while commercial success still depends on competition and execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
